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Abstract We recently reported the molecular identification of a
new type of receptor for the neuropeptide neurotensin (NT), the
neurotensin receptor 3 (NTR3), identical to sortilin, which binds
receptor-associated protein. Here, we demonstrate that the
cloned mouse NTR3 is expressed on the plasma membrane of
transfected COS-7 cells. The mouse NTR3 is detectable by
photoaffinity labeling and immunoblotting at the cell surface as a
100 kDa N-glycosylated protein. Biochemical analysis and
confocal microscopic imaging clearly indicate that NT is
efficiently internalized after binding to NTR3, and that despite
this internalization, the amount of receptor present on the cell
surface is maintained. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Among the three identi¢ed neurotensin (NT) receptors,
NTR1 and NTR2 belong to the family of G protein-coupled
receptors (GPCRs) [1^3], whereas the latest cloned protein
NTR3 represents a new type of neuropeptide receptor [4].
Indeed, this NTR, also named sortilin, is a typical type 1
membrane protein with a large luminal domain, a single trans-
membrane domain and a short cytoplasmic tail [5]. NTR3
binds both NT and the 39 kDa receptor-associated protein
(RAP), an endoplasmic reticulum-resident protein [6]. The
receptor is synthesized as an inactive precursor which binds
ligands only after furin cleavage in late Golgi [7], and also
binds lipoprotein lipase (LpL) [8].
The high a⁄nity NT receptor (NTR1) as well as the levo-
cabastine-sensitive NT receptor (NTR2) are both expressed on
the plasma membrane (PM) of transfected cells, and their
binding to NT can be demonstrated using whole cells as
well as membrane homogenates [9,10]. The transduction
mechanism of NTR2 has not been clearly established [2,10],
whereas the coupling of the NTR1 to phospholipase C was
demonstrated in several eukaryotic expression systems
[9,11,12]. Both receptors are internalized after NT binding
[10,13], suggesting a functional regulation of their cell surface
expression. However, the sorting of internalized NTR1 and
NTR2 di¡ers since the NTR2 recycles to the PM whereas
the NTR1 remains intracellularly sequestered [10,13].
The binding of NTR3 to RAP and NT was originally es-
tablished using 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonic acid (CHAPS)-solubilized extracts of human
brain membranes and transfected COS cells [4,5]. These re-
ports demonstrated that a large pool of NTR3 was localized
in Golgi and intracellular vesicles. However, recent studies
demonstrated that in response to insulin, NTR3 was trans-
located with the glucose transporter Glut4 to the PM in rat
adipocytes [14,15], and more recently, NTR3 was shown to
mediate uptake and degradation of the LpL [8]. However,
nothing is known about the interaction of NT with the
NTR3 present at the PM of eukaryotic cells. In this work,
we isolated the mouse brain counterpart of the human NTR3.
We also showed for the ¢rst time that NT is able to bind the
expressed receptor when present at the PM of transfected
COS-7 cells. This binding is followed by a rapid and su-
crose-sensitive internalization of the ligand^receptor complex
but the amount of receptor at the cell surface remained un-
changed.
2. Materials and methods
2.1. Materials
NT was from Peninsula Laboratories and NT(2^13) was synthe-
sized by Neosystem. SR48692 was from Sano¢ Recherche. 125I-
Tyr3-NT, K-azidobenzoyl-125I-Tyr3-NT(2^13), and £uorescent NT
were prepared and puri¢ed as described previously [16^18]. The
pTARGET expression vector was from Promega. Taq DNA polymer-
ase and reagents for PCR were from Appligene, oligonucleotides from
Eurogentec, Dulbecco’s modi¢ed Eagle’s medium from Life Technol-
ogies Inc. CHAPS, cholesteryl hemisuccinate (CHS), gentamicin, 1,10-
phenanthroline, phenylarsine oxide (PheAsO) and monensin were
from Sigma France, and fetal calf serum was from Roche Diagnostics.
2.2. cDNA cloning and expression of the mouse NTR3
106 clones derived from the mouse cDNA library [2] were screened
by hybridization with a HindIII fragment (900 bp) of the human
NTR3 cDNA as previously described [2]. One hybridization-positive
clone was isolated by repeated puri¢cation. Both strands were se-
quenced using the ABI-Prism DNA sequencing kit (Applied Biosys-
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tems, Foster City, CA). The 2.5 kb corresponding to the coding re-
gion of the mouse NTR3 was subcloned after PCR ampli¢cation into
the eukaryotic expression vector pTARGET.
Transient transfections were performed with 1^5 Wg of recombinant
vector by the DEAE-dextran precipitation method [19]. Binding and
internalization assays were performed either on cells plated in 12 mm
cell culture dishes or on CHAPS-solubilized extracts prepared approx-
imately 60 h after transfection.
2.3. Solubilization of mNTR3 and binding assay
Cell homogenates were solubilized as previously described [4].
CHAPS-solubilized extracts (25 Wg of protein) were incubated with
125I-Tyr3-NT (2000 or 50 Ci/mmol) for 1 h at 0‡C in 250 Wl of 25 mM
Tris^HCl (pH 7.4), 0.1% CHAPS (w/v) and 0.02% CHS (w/v)
(CHAPS bu¡er). Bound ligand was separated from free ligand by
¢ltration on GF/B ¢lters pretreated with 0.3% polyethyleneimine [9].
Non-speci¢c binding was determined in the presence of 1 WM unla-
beled NT. Crude and CHAPS-solubilized homogenates from non-
transfected COS-7 cells were totally devoid of speci¢c 125I-Tyr3-NT
binding.
2.4. Binding experiments to transfected cells
Kinetics experiments were performed on cells plated in 12 mm cell
culture dishes. Cells (2U105) were equilibrated for 10 min in an
Earle’s Tris^HEPES bu¡er, pH 7.5, supplemented with 0.1% glucose
and 0.1% bovine serum albumin in the presence or in the absence of
0.45 M sucrose or 10 WM PheAsO, an internalization blocker [17].
The equilibration bu¡er was then replaced by 250 Wl of binding bu¡er
containing 0.4 nM 125I-Tyr3-NT in the presence of 0.8 mM 1,10-phen-
anthroline for various periods of time at 37‡C. At the end of incuba-
tion, cells were washed twice with 0.5 ml of equilibration bu¡er or
with 0.5 ml of the same bu¡er containing 0.5 M NaCl (pH 4) twice for
2 min to remove non-sequestered radioactivity. Cells were harvested
with 0.1 N NaOH and counted in a Q counter. Non-speci¢c binding
was determined with 1 WM unlabeled NT.
Saturation experiments were performed in the presence or in the
absence of 25 WM monensin, a recycling inhibitor [17], using concen-
trations from 0.5 to 10 nM 125I-Tyr3-NT (200 Ci/mmol). In parallel
experiments, cells were also incubated as above in the presence of 0.45
M sucrose which inhibited clathrin-dependent sequestration. At the
end of incubation, cells were washed, harvested and counted as de-
scribed above.
2.5. Measurement of cell surface receptor translocation
Transfected COS-7 cells were incubated for various times at 37‡C
with 100 nM of NT. Free peptide and peptide remaining bound to the
cell surface were removed by a series of washes with ice-cold bu¡ers:
three washes with Earle’s bu¡er, pH 7.5, two washes with 150 mM
NaCl, 5 mM acetic acid, and three washes with the Earle’s bu¡er.
Finally, the amount of cell surface receptors was measured as de-
scribed above in the presence of the internalization blocker PheAsO.
2.6. Photoa⁄nity labeling on whole cells
K-Azidobenzoyl-125I-Tyr3-NT(2^13) (0.25 nM) was incubated in the
absence or in the presence of 10 WM PheAsO for 30 min in the dark at
37‡C with whole COS-7 cells transfected with the mNTR3 cDNA.
Non-speci¢c labeling was determined in the presence of 10 WM NT.
Cells were then washed twice for 2 min either with ice-cold binding
bu¡er or with the same bu¡er containing 0.5 M NaCl (pH 4) and
directly irradiated on ice for 10 min with a 6 W UV lamp (253 nm).
Cells were scraped and analyzed by SDS^PAGE as previously de-
scribed [13]. Radiolabeled bands were ¢nally detected using a Phos-
phorimager.
2.7. Subcellular fractionation and Western blot analysis
Cells transfected with the cDNA of the mNTR3 were either left in
the basal state or treated with 100 nM NT for 30 min and homoge-
nized in 0.25 M sucrose, 20 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM
PMSF, then subjected to di¡erential centrifugation as previously
described [20]. Proteins of each fraction were assayed for
NaKATPase activity. A six-fold enrichment in enzyme activity
was found in the PM fraction by comparison with whole cell homo-
genates whereas the other fractions were devoid of NaKATPase
activity. Proteins recovered from di¡erent fractions were separated
on an 8% polyacrylamide gel according to Laemmli [21], and trans-
ferred on nitrocellulose membranes. Immunoblotting was performed
as previously described [5] using a 1:1000 dilution of anti-NTR3 anti-
body, and revealed by the Lumilight enhanced chemiluminescence
method (Roche Diagnostics).
2.8. Confocal microscopic studies
Cells transfected with the mNTR3 were grown on glass microscope
slides pretreated with polylysine (10 Wg/ml) and incubated for 30 min
at 37‡C in Earle’s bu¡er, pH 7.5, containing 20 nM K-BODIPY-
NT(2^13). Cells were washed with the hypertonic acid bu¡er as above
and air-dried before confocal microscopy. For immunocytochemistry,
after incubation with 100 nM NT for 30 min at 37‡C, cells were ¢xed
for 20 min at room temperature with 4% paraformaldehyde in phos-
phate-bu¡ered saline (PBS). For conditions allowing permeabiliza-
tion, cells were treated in PBS containing 10% horse serum and
0.05% Triton X-100 for 20 min at room temperature before incuba-
tion with the NTR3 antibody (1:300) in PBS containing 5% horse
serum and 0.05% Triton X-100 for 1 h at room temperature. Finally,
cells were incubated with the secondary Texas red donkey anti-rabbit
antibody (1:500) (Jackson Immunoresearch Laboratories, Inc.) for 1 h
at room temperature in the bu¡er used above. To visualize the cell
surface labeling (without permeabilization), cells were treated in iden-
tical conditions in the absence of Triton X-100. Permeabilized and
non-permeabilized cells were mounted in Mowiol (Sigma) and exam-
ined under a Leica inverted microscope equipped with an argon/kryp-
ton laser. Images of cells were acquired as single optical sections taken
through the middle of the cells and averaged over 32 scans/frame.
3. Results
The screening of a mouse brain cDNA library [2] allowed
us to isolate a single clone of 8.5 kb. The largest open reading
frame of this cDNA encodes a protein of 825 amino acids
(GenBank, AAF22639) which shares 95% and 92% identity
with the rat and human NTR3, respectively [4,5,14]. All the
structural elements described for human NTR3 were pre-
served in the mouse counterpart including the furin cleavage
site.
3.1. Speci¢city of the cloned mouse NTR3
The binding properties of the mNTR3 were ¢rst character-
ized on CHAPS-solubilized extracts of COS-7 cells transiently
transfected with the cloned cDNA. The abilities of NT ago-
nists or antagonists and of unrelated peptides to inhibit the
binding of 125I-Tyr3-NT to the CHAPS-solubilized mNTR3
and whole cells were compared to data obtained using the
solubilized human NTR3 [4]. As shown in Table 1, the phar-
macological pro¢les were similar since NT and Trp11NT were
more potent than NN and D-Trp11NT. The non-peptide an-
tagonist SR48692 and levocabastine were unable to inhibit
125I-Tyr3-NT binding to solubilized extracts as well as to
whole cells at concentrations below 10 WM (Table 1). We
also tested the ability of RAP to inhibit the binding of NT
on whole COS cells expressing mNTR3; RAP competed with
iodinated NT with an IC50 of 100 þ 8 nM (n = 2), a value close
to that obtained for RAP binding to puri¢ed soluble minire-
ceptors secreted by CHO cells [7].
3.2. Binding and internalization of the mouse NTR3 expressed
in eukaryotic cells
Kinetics of the 125I-Tyr3-NT association to transfected
COS-7 cells at 37‡C showed that a large fraction of bound
ligand (about 75% at 60 min) was resistant to the hypertonic
acid wash (Fig. 1A) and then represented internalized ligand.
In the presence of hyperosmotic sucrose (0.45 M), conditions
which block the clathrin-dependent endocytosis, the hyperton-
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ic acid wash totally dissociated 125I-Tyr3-NT bound to cells
(Fig. 1A). Experiments performed in the presence of PheAsO
or at 4‡C showed kinetic pro¢les identical to those obtained in
sucrose (not shown).
The speci¢c binding of 125I-Tyr3-NT at 37‡C to COS-7 cells
expressing the mNTR3 was concentration-dependent and sat-
uration was obtained at concentrations up to 200 nM (Fig.
1B). The Kd value was about 40 nM and the maximal binding
capacity (Bmax) reached 500 fmol/mg protein, a value similar
to that observed in neurons (250 fmol/mg [17]). However, in
the presence of hyperosmotic sucrose, which makes it possible
to determine the amount of receptor initially present at the
cell surface, the Bmax was 100 fmol/mg protein, whereas the
Kd value was not a¡ected (36 þ 7 nM). In the presence of the
recycling inhibitor monensin, the Bmax was 250 fmol/mg pro-
tein, a value indicating that part of the binding measured at
37‡C in the absence of drug was due to recycling of internal-
ized receptor.
3.3. Photoa⁄nity labeling experiments
COS-7 cells transfected with the mNTR3 were covalently
labeled with 125I-Tyr3-K-azido-NT(2^13) under various exper-
imental conditions (Fig. 2). Autoradiogram revealed that a
single protein with a Mr of about 100 kDa was speci¢cally
labeled at 37‡C (Fig. 2). The labeling of the 100 kDa protein
remained intense after hypertonic acid treatment which disso-
ciates the surface-bound ligand. In the presence of PheAsO,
the same 100 kDa protein was labeled but with a weaker
intensity. This labeling corresponded to the labeling of the
Table 1
Compared IC50 values of NT and its related compounds in competition experiments with 125I-Tyr3-NT on CHAPS-solubilized extracts from
COS-7 cells expressing human [4] or mouse NTR3 and on whole cells expressing the mNTR3
Solubilized hNTR3 Solubilized mNTR3 Whole cells mNTR3
NT 17 nM 45 þ 8 nM 40 nM
Trp11-NT 17 nM 10 þ 5 nM 60 þ 14 nM
Neuromedin N 63 nM s 1 WM 600 þ 100 nM
D-Trp11-NT 72 nM s 1 WM 1 WM
Xenin s 1 WM 219 þ 5 nM 215 þ 30 nM
Levocabastine s 10 WM s 10 WM s 10 WM
SR48692 3 WM s 10 WM s 10 WM
The values represent the mean þ S.E.M. from at least three independent experiments performed in duplicate.
Fig. 1. Binding properties of the mouse NTR3 on whole COS-7
cells. A: Kinetics for 125I-Tyr3-NT binding to whole COS-7 cells ex-
pressing the mouse NTR3. Incubations were performed in the pres-
ence (circles) or in the absence (squares) of 0.45 M sucrose, fol-
lowed (closed symbols) or not (open symbols) by an acid NaCl
wash. Values are expressed as the percent of total cell-associated li-
gand at each time. Each point represents the mean þ S.E.M. of at
least three di¡erent experiments with duplicate determination.
B: Saturation of speci¢c 125I-Tyr3-NT binding to whole COS-7 cells
expressing the mouse NTR3. Experimental details are described in
Section 2. Brie£y, cells were incubated at 37‡C with increasing con-
centrations of 125I-Tyr3-NT in the absence (open squares) or in the
presence of 25 WM monensin (open circles) or 0.45 M sucrose
(closed squares). Results are expressed as the mean þ S.E.M. from
three di¡erent experiments.
Fig. 2. Photoa⁄nity labeling of COS-7 cells expressing the mouse
NTR3 using K-azidobenzoyl-125I-Tyr3-NT(2^13). Cells were incu-
bated in the dark with 0.25 nM of K-azidobenzoyl-125I-Tyr3-NT(2^
13) for 30 min at 37‡C in the presence (e^h) or in the absence (a^d)
of 10 WM PheAsO. The non-speci¢c labeling was obtained in the
presence of 10 WM NT. Cells were washed with either ice-cold bu¡-
er (a, b, e, f) or hypertonic acid bu¡er (c, d, g, h) and irradiated by
a UV lamp for 10 min at 4‡C. Samples were analyzed by SDS^
PAGE and radiolabeled bands were detected with a Phosphorimag-
er.
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cell surface receptor since it totally disappeared after the acid
wash (Fig. 2). No labeling was observed on non-transfected
cells (not shown).
3.4. Western blot analysis of subcellular fractions of COS-7
cells expressing the mNTR3
To quantify the amount of mNTR3 present in the PM and
in other subcellular fractions, cells transfected with the
mNTR3 were incubated in the absence or in the presence of
NT and fractionated to separate the PM, the high and low
density microsomes (HDM and LDM), the nuclear fraction
and the cytosol (Cyto). On total cell extract, two proteins with
Mr of 90 and 100 kDa, respectively, were detected with the
anti-luminal NTR3 antibodies (Fig. 3A, lane 1). Treatment of
cells with tunicamycin prevented the formation of the 100
kDa protein (Fig. 3A, lane 2) suggesting, in agreement with
previous observations [7], that a large portion of the mNTR3
was N-glycosylated. Only the glycosylated form of mNTR3
(100 kDa) was present on the PM (Fig. 3B, lanes 1 and 2). In
the fraction of LDM and HDM, the two 90 and 100 kDa
forms were visualized, the larger (i.e. the glycosylated) form
being predominant (Fig. 3B, lanes 3 and 4). The Cyto was
devoid of NTR3 protein (Fig. 3B, lanes 5 and 6) whereas the
nuclear/mitochondrial fraction was enriched in both the 90
and 100 kDa forms of receptor (Fig. 3B, lanes 7 and 8).
Quanti¢cation by scanning of the 100 kDa protein in each
fraction revealed that the PM contained about 20% of the
total cell amount of mNTR3 detected by Western blot anal-
ysis. Incubation with 0.1 WM NT increased the amount of
mNTR3 to the PM (Fig. 3B, lanes 1 and 2). This e¡ect was
also observed in experiments carried out on whole COS cells
on which unlabeled NT (0.1 WM) was added for various times
at 37‡C, extensively washed, and the binding to the cell sur-
face was measured in the presence of the internalization
blocker PheAsO. In these conditions, NT increased the
amount of cell surface binding to 130% from the basal level
(Fig. 3C) whereas the other NTR3 ligand RAP was ine¡ec-
tive.
3.5. Confocal imaging of the mNTR3 in transfected COS-7
cells
Immunolabeling of transfected cells incubated with or with-
out unlabeled NT is shown in Fig. 4A^C. In the absence of
NT, immunocytochemistry revealed that receptors were
present at the cell surface (Fig. 4A) but the prominent labeling
was intracellular (Fig. 4C). Following exposure to NT, NTR3
immuno£uorescence was still constant at the surface of the
cell (Fig. 4B) although the peptide, as visualized by labeling
obtained with Fluo-NT, was intensively internalized through-
out the cell (Fig. 4D), suggesting that the amount of NTR3
present at the cell surface remained constant.
Fig. 3. Western blot analysis of subcellular distribution of mNTR3
in transfected COS-7 cells. A: Cells were incubated (overnight at
37‡C) with (lane 2) or without (lane 1) 1 Wg/ml tunicamycin, and to-
tal cell extracts were separated by SDS^PAGE and immunoblotted
for mNTR3. B: Cells were incubated in the presence (lanes 2, 4, 6,
8) or absence (lanes 1, 3, 5, 7) of 100 nM NT for 30 min at 37‡C.
Subcellular fractions were obtained as described in Section 2 and 30
Wg of proteins corresponding to PM, HDM and LDM, Cyto, and
mitochondria/nuclei (M/N) were separated and analyzed as de-
scribed in A. Each experiment was carried out three times. Results
from one representative experiment are shown. C: Determination of
the cell surface number of NTR3. Cells transfected with the
mNTR3 were incubated for various times at 37‡C with 100 nM NT
(closed symbols) or with 100 nM RAP (open symbols). After exten-
sive washes, 125I-Tyr3-NT binding was performed at 37‡C in the
presence of 10 WM PheAsO to prevent membrane tra⁄cking (inter-
nalization, recycling). Values are expressed as percent of the amount
of receptor measured in the absence of treatment and are means
þ S.E.M. from three independent experiments performed in tripli-
cates.
Fig. 4. Confocal microscopic imaging of COS-7 transfected with the
mNTR3. The receptor was visualized by immunocytochemistry (A^
C) and the ligand with Fluo-NT (D) as described in Section 2. Cells
were incubated without the peptide (A and C) or with 100 nM NT
(B). Immunolabeling protocol was carried out in the absence (non-
permeabilized, A and B) or in the presence of Triton X-100 (per-
meabilized, C). In D, cells were incubated with 20 nM Fluo-NT for
20 min at 37‡C, washed with the hypertonic acid bu¡er and air
dried. Single trans-nuclear optical sections were scanned Scale bar:
10 Wm.
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4. Discussion
The major ¢nding of this work is that the mouse NTR3
protein is expressed in part on the PM of transfected cells
where it recognizes and internalizes NT. This is the ¢rst direct
demonstration that the NTR3 is able to bind NT when
present at the cell surface. Indeed, our previous works de-
scribed the binding of NT only to CHAPS-solubilized brain
or cell extracts [4,22]. Although the amount of cell surface
receptors is relatively low under basal conditions, the inter-
action with NT appears to induce the translocation of the
protein to the cell surface suggesting a dynamic regulation
of the protein subcellular localization. This ¢nding is consis-
tent with a recent work which reported that CHO cells trans-
fected with NTR3 expressed about 10% of receptors on the
cell surface and mediated endocytosis and degradation of LpL
[8].
Interestingly, under conditions which allow internalization
and recycling, binding saturation was obtained only at con-
centrations of the NT close to 200 nM. These results suggest
that in COS-7 cells, NTR3 may accumulate the peptide into
the cell by a mechanism involving recruitment of intracellular
receptors to the membrane, internalization of the ligand^
receptor complexes and recycling of the receptor after disso-
ciation of the ligand, thus acting as a scavenger for NT. Sim-
ilar conclusions have been drawn for another type I receptor,
the cation-independent mannose 6-phosphate/insulin growth
factor-II (IGF II) receptor, which has been shown to inter-
nalize IGF II and may serve to clear it from the circulation
[23].
The pharmacological pro¢le of mNTR3 on whole cells is
very similar to that measured on CHAPS-solubilized extracts
from cells transfected with either human or mouse NTR3
cDNA. Indeed, NT and Trp11NT display equivalent potencies
to inhibit the binding of 125I-Tyr3-NT (IC50 = 20^40 nM)
whereas levocabastine and the non-peptide antagonist
SR48692 are poorly e⁄cient (IC50s 3 WM). The only marked
di¡erence between the human and the mouse NTR3 is ob-
served with neuromedin N which is 10^20 fold less potent
on the mouse NTR3 than on the human counterpart.
Western blot analysis performed on total cell extracts re-
veals the expression of two proteins with Mr of 100 and 90
kDa, respectively, the high molecular weight form corre-
sponding to the N-glycosylated protein. Interestingly, only
the glycosylated protein is present at the cell surface whereas
the HDM/LDM fraction contains a small proportion of the
non-glycosylated form. A large amount of the two NTR3
forms is found in the nuclear/mitochondrial fraction, a result
suggesting a possible involvement of the NTR3 in some nu-
clear gene activation as suggested by the role of the receptor
on the growth e¡ects of NT in several cancer cell lines [24].
From Western blot analysis, we can conclude that the mouse
NTR3 is expressed on the PM as a glycosylated protein that
could be a functional receptor for NT. Photoa⁄nity labeling
experiments con¢rm that only the higher molecular weight
100 kDa protein is present at the cell surface (Fig. 2). Note
that in the presence of the internalization blocker PheAsO
making it possible to detect the labeling of the NTR3 initially
present on the cell surface, the labeling intensity is lower than
in conditions where sequestration and accumulation of the
ligand is allowed. These data are in agreement with the rela-
tively low amount of the protein detected by Western blot
analysis in the PM fraction (between 10 and 20%). Interest-
ingly, although NT is e⁄ciently internalized with NTR3, the
amount of receptor present in the PM is maintained, an ob-
servation measured both by Western blot, binding experi-
ments, and visualized by confocal imaging in the absence of
permeabilization. This e¡ect is NT-speci¢c since RAP, anoth-
er known ligand for NTR3, has no in£uence on the protein
membrane translocation. This result suggests that NT may
induce a speci¢c activation of a signaling pathway leading
to the transport of NTR3 from intracellular compartments
to the cell surface. These observations are in agreement with
data obtained in primary cultures of neurons naturally ex-
pressing NT binding sites [17]. In these cells, NT was shown
to be e⁄ciently internalized by a 100 kDa protein after induc-
ing its translocation from an intracellular compartment to the
PM [17]. Although the cellular mechanisms by which this
regulation is mediated are not known, the mNTR3 can be
actually considered a receptor for NT since the peptide trig-
gers the growth of CHO cells expressing the protein [24].
In conclusion, we have shown that the mouse NTR3 is
present on the cell surface, that the receptor mediates the
binding and the internalization of NT, and that its presence
on the surface membrane is regulated by the peptide.
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